MIST on Nasdaq

Milestone Pharmaceuticals Inc.

Canadian pharmaceutical preparations company, incorporated in Quebec. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with another stock.

  • TickerMIST on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersMontreal, Canada1
  • Incorporated inQuebec, Canada2
  • Business address1111 Boul. Dr.-Frederik-Philips, Ste 420, Montreal, A8 H4M 2X62
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

We are currently focusing our efforts and financial resources on (i) the commercialization of CARDAMYST TM (etripamil) nasal spray for the treatment of PSVT, (ii) the development of etripamil for the treatment of AFib-RVR and (iii) corporate development activities that have the potential to increase company value through strategic collaborations.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income456789-$62.1M in 2025+7% since 2019
-$80.0M-$60.0M-$40.0M-$20.0M02019: -$57.9M-$57.9M20192020: -$50.7M-$50.7M2020−12%2021: -$43.1M-$43.1M2021−15%2022: -$59.6M-$59.6M2022+38%2023: -$61.1M-$61.1M2023+2%2024: -$42.1M-$42.1M2024−31%2025: -$62.1M-$62.1M2025+48%
Net income456789-$63.1M in 2025+14% since 2019
-$80.0M-$60.0M-$40.0M-$20.0M02019: -$55.2M-$55.2M20192020: -$50.0M-$50.0M2020−10%2021: -$42.9M-$42.9M2021−14%2022: -$58.4M-$58.4M2022+36%2023: -$59.7M-$59.7M2023+2%2024: -$41.5M-$41.5M2024−30%2025: -$63.1M-$63.1M2025+52%

Every line of the income statement as filed: the last 2 fiscal years, latest first.9

Period ending2025-12-312024-12-31
Revenue$1.5M$0
Research and development, net of tax credits$18.1M$14.4M
General and administrative$17.3M$16.7M
Commercial$28.3M$11.0M
Loss from operations-$62.1M-$42.1M
Interest income$2.9M$4.2M
Interest expense-$3.8M-$3.6M
Net loss and comprehensive loss-$63.1M-$41.5M
Weighted average number of shares and pre-funded warrants outstanding, basic (in shares)83.9M shares62.2M shares
Weighted average number of shares and pre-funded warrants outstanding, diluted (in shares)83.9M shares62.2M shares
Net loss per share, basic (in dollars per share)-$0.75-$0.67
Net loss per share, diluted (in dollars per share)-$0.75-$0.67

Compare Milestone Pharmaceuticals Inc. with another company

Leadership

Who has led Milestone Pharmaceuticals Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Joseph Oliveto2019–now

President

  1. Joseph Oliveto2019–now

Chief financial officer

  1. Amit Hasija2019–now
20202025
Board members and other officers (18)

Timeline

  1. May 8, 2019New chief executive Joseph Oliveto becomes CEO13

Filings

252 filings to the SEC since October 2021: 7 annual reports, 15 quarterly reports, 54 major events, 90 insider forms, 35 large holders, 51 other. The latest 20:

  1. Sep 3, 20268-K EDGAR
  2. Aug 12, 20268-K EDGAR
  3. Aug 12, 202610-Q EDGAR
  4. Aug 7, 2026SCHEDULE 13G EDGAR
  5. Jun 15, 20268-K EDGAR
  6. Jun 12, 20264 EDGAR
  7. Jun 12, 20264 EDGAR
  8. Jun 12, 20264 EDGAR
  9. Jun 12, 20264 EDGAR
  10. Jun 12, 20264 EDGAR
  11. Jun 12, 20264 EDGAR
  12. Jun 12, 20264 EDGAR
  13. May 22, 2026EFFECT EDGAR
  14. May 20, 2026CORRESP EDGAR
  15. May 18, 2026UPLOAD EDGAR
  16. May 15, 2026SCHEDULE 13G/A EDGAR
  17. May 13, 2026S-3 EDGAR
  18. May 13, 20268-K EDGAR
  19. May 13, 202610-Q EDGAR
  20. May 13, 2026SCHEDULE 13G/A EDGAR

The 252 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

23 open-market trades by officers, directors and large owners since October 2021: 9 buys and 14 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Apr 16, 2026Oliveto JosephPresident and CEOSale36,500$2.26$82.5KForm 4
Jan 26, 2026Nelson Jeffrey EdwardChief Operating OfficerSale12,245$1.93$23.6KForm 4
Jan 26, 2026Bharucha DavidChief Medical OfficerSale12,245$1.93$23.6KForm 4
Jan 26, 2026Hasija AmitCFO & EVP of Corp. DevelopmentSale12,245$1.93$23.6KForm 4
Jan 26, 2026Muller LorenzChief Commercial OfficerSale11,180$1.93$21.6KForm 4
Jan 26, 2026Oliveto JosephPresident and CEOSale34,523$1.93$66.6KForm 4
Jan 8, 2026Oliveto JosephPresident and CEOSale43,000$2.25$96.8KForm 4
Jan 7, 2026Oliveto JosephPresident and CEOSale500$2.25$1.1KForm 4
Dec 15, 2025Nelson Jeffrey EdwardChief Operating OfficerSale58,007$2.32$134.6KForm 4
Dec 15, 2025Bharucha DavidChief Medical OfficerSale58,007$2.32$134.6KForm 4
Dec 15, 2025Hasija AmitCFO & EVP of Corp. DevelopmentSale58,007$2.32$134.6KForm 4
Dec 15, 2025Muller LorenzChief Commercial OfficerSale53,566$2.32$124.3KForm 4
Dec 15, 2025Oliveto JosephPresident and CEOSale133,054$2.32$308.7KForm 4
Dec 5, 2022Bharucha DavidChief Medical OfficerBuy7,000$4.69$32.8KForm 4
Dec 1, 2022Bharucha DavidChief Medical OfficerBuy3,000$4.86$14.6KForm 4
Oct 21, 2022Liebert Debra K.DirectorBuy4,000$5.26$21.0KForm 4
Oct 20, 2022Pasternak Richard CDirectorBuy10,000$5.20$52.0KForm 4
Oct 20, 2022Liebert Debra K.DirectorBuy10,000$5.29$52.9KForm 4
Oct 19, 2022Wills Robert JamesDirectorBuy15,000$4.93$74.0KForm 4
Oct 19, 2022TOMSICEK MICHAEL JOHNDirectorBuy15,000$5.32$79.8KForm 4

All 23 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 78. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Pavaki Capital Management LLC9,067,848$12.2M6.9%+5,000
Rtw Investments, LP7,833,336$10.5M0.1%+1,502,335
Propel Bio Management, LLC7,429,590$10.0M5.2%+3,311,269
Point72 Asset Management, L.P.5,411,138$7.3M0.0%+4,325,455
Simplify Asset Management Inc.3,349,379$4.5M0.1%+1,842,974
Millennium Management LLC3,142,219$4.2M0.0%+1,597,894
Kalehua Capital Management LLC2,538,474$3.4M1.1%New
Two Sigma Investments, LP2,040,015$2.7M0.0%−277,161
Marshall Wace, Llp1,797,695$2.4M0.0%−146,835
Lion Point Capital, LP820,000$1.1M5.3%No change
Toronto Dominion Bank750,000$1.0M0.0%No change
Ameriprise Financial Inc666,666$893.3K0.0%No change
Boxer Capital Management, LLC666,666$893.3K0.1%No change
Morgan Stanley635,211$851.2K0.0%−88,930
UBS Group AG465,403$623.6K0.0%−29,505
Boothbay Fund Management, LLC462,669$620.0K0.0%+293,994
Susquehanna International Group, Llp359,895$482.3K0.0%−159,151
Aptus Capital Advisors, LLC339,450$454.9K0.0%+59,200
Guardian Wealth Advisors, LLC / Nc339,450$454.9K0.0%+59,200
Seven Fleet Capital Management LP270,233$362.1K0.1%−63,100
Squarepoint Ops LLC231,824$310.6K0.0%−105,001
LPL Financial LLC220,873$296.0K0.0%+27,500
Balyasny Asset Management L.P.220,498$295.5K0.0%−630,827
Bnp Paribas Financial Markets173,704$232.8K0.0%−2,800
Tru Independence Asset Management 2, LLC150,000$201.0K0.1%+50,000

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45